» Articles » PMID: 36552984

A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics

Overview
Specialty Radiology
Date 2022 Dec 23
PMID 36552984
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a polygenic multifactorial neurodegenerative disease that, after decades of research and development, is still without a cure. There are some symptomatic treatments to manage the psychological symptoms but none of these drugs can halt disease progression. Additionally, over the last few years, many anti-AD drugs failed in late stages of clinical trials and many hypotheses surfaced to explain these failures, including the lack of clear understanding of disease pathways and processes. Recently, different epigenetic factors have been implicated in AD pathogenesis; thus, they could serve as promising AD diagnostic biomarkers. Additionally, network biology approaches have been suggested as effective tools to study AD on the systems level and discover multi-target-directed ligands as novel treatments for AD. Herein, we provide a comprehensive review on Alzheimer's disease pathophysiology to provide a better understanding of disease pathogenesis hypotheses and decipher the role of genetic and epigenetic factors in disease development and progression. We also provide an overview of disease biomarkers and drug targets and suggest network biology approaches as new tools for identifying novel biomarkers and drugs. We also posit that the application of machine learning and artificial intelligence to mining Alzheimer's disease multi-omics data will facilitate drug and biomarker discovery efforts and lead to effective individualized anti-Alzheimer treatments.

Citing Articles

Gintonin Binds to Reduced LPA4 Receptor Subtype in Human Cortical Neurons in Alzheimer's Disease Brains.

Kim K, Lee R, Park I, Hwang S, Kim Y, Jang J Biomolecules. 2025; 15(2).

PMID: 40001482 PMC: 11853258. DOI: 10.3390/biom15020179.


Enhancement of Cognitive Benefits and Anti-Anxiety Effects of Fruits in a Zebrafish () Model of Scopolamine-Induced Memory Impairment.

Popovici L, Brinza I, Gatea F, Badea G, Vamanu E, Oancea S Antioxidants (Basel). 2025; 14(1).

PMID: 39857431 PMC: 11762548. DOI: 10.3390/antiox14010097.


Moroccan natural products for multitarget-based treatment of Alzheimer's disease: A computational study.

Guerguer F, Bouribab A, Karim E, Khedraoui M, Amegrissi F, Raouf Y PLoS One. 2025; 20(1):e0313411.

PMID: 39820594 PMC: 11737685. DOI: 10.1371/journal.pone.0313411.


Role of NRF2 in Pathogenesis of Alzheimer's Disease.

Chu C, Uruno A, Katsuoka F, Yamamoto M Antioxidants (Basel). 2025; 13(12.

PMID: 39765857 PMC: 11727090. DOI: 10.3390/antiox13121529.


The application of artificial intelligence in diagnosis of Alzheimer's disease: a bibliometric analysis.

An X, He J, Bi B, Wu G, Xu J, Yu W Front Neurol. 2024; 15:1510729.

PMID: 39703357 PMC: 11655329. DOI: 10.3389/fneur.2024.1510729.


References
1.
Chandra N, Padiadpu J . Network approaches to drug discovery. Expert Opin Drug Discov. 2012; 8(1):7-20. DOI: 10.1517/17460441.2013.741119. View

2.
Vaz M, Silvestre S . Alzheimer's disease: Recent treatment strategies. Eur J Pharmacol. 2020; 887:173554. DOI: 10.1016/j.ejphar.2020.173554. View

3.
El-Sappagh S, Alonso J, Islam S, Sultan A, Kwak K . A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease. Sci Rep. 2021; 11(1):2660. PMC: 7846613. DOI: 10.1038/s41598-021-82098-3. View

4.
Vogt N, Kerby R, Dill-McFarland K, Harding S, Merluzzi A, Johnson S . Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017; 7(1):13537. PMC: 5648830. DOI: 10.1038/s41598-017-13601-y. View

5.
Lunnon K, Mill J . Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B(8):789-99. PMC: 3947441. DOI: 10.1002/ajmg.b.32201. View